Table 3.
Other medication use in the 6 months prior to and after tofacitinib initiation
| Overall | Biologic-naïve | 1 prior biologic | ≥ 2 prior biologics | |||||
|---|---|---|---|---|---|---|---|---|
| N = 225 | N = 43 | N = 92 | N = 90 | |||||
| 6-month baseline | 6-month follow-up | 6-month baseline | 6-month follow-up | 6-month baseline | 6-month follow-up | 6-month baseline | 6-month follow-up | |
| 5-ASA, n (%) | 112 (49.8) | 70 (31.1) | 25 (58.1) | 16 (37.2) | 49 (53.3) | 30 (32.6) | 38 (42.2) | 24 (26.7) |
| Immunomodulator, n (%) | 68 (30.2) | 21 (9.3) | 3 (7.0) | 4 (9.3) | 31 (33.7) | 14 (15.2) | 34 (37.8) | 3 (3.3) |
| Oral corticosteroids, n (%)a | 148 (65.8) | 93 (41.3) | 32 (74.4) | 10 (23.3) | 56 (60.9) | 39 (42.4) | 60 (66.7) | 44 (48.9) |
| Daily dose, mg/day, mean (SD)b | 31.5 (16.2) | 28.2 (13.5) | 30.1 (18.2) | 22.5 (17.9) | 33.6 (19.7) | 26.6 (14.1) | 30.4 (10.6) | 30.9 (11.3) |
Baseline was defined as the 6 months prior to index date. Follow-up period was 6 months following the index date
5-ASA, 5-aminosalicylates; n, number of patients in the specified category; N, number of patients in the treatment group; TNFi, tumour necrosis factor inhibitor
aBased on pharmacy claims only
bPrednisone equivalent